Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Human papillomavirus vaccines.

Margaret A Stanley1

  • 1Department of Pathology, Cambridge, UK. mas@mole.bio.cam.ac.uk

Reviews in Medical Virology
|May 20, 2006
PubMed
Summary
This summary is machine-generated.

Prophylactic human papillomavirus (HPV) vaccination shows promise in preventing cervical cancer by targeting HPV infections. Current HPV L1 VLP vaccines are safe and effective, but duration of protection and type specificity require further study.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Meeting report: Considerations for trial design and endpoints in licensing therapeutic HPV16/18 vaccines to prevent cervical cancer.

Vaccine·2024
Same author

Possible Reactivation of Latent Anal Human Papillomavirus Associated with Markers of Immune Dysfunction in Gay and Bisexual Men.

Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology·2022
Same author

Current and future vaccine clinical research with the licensed 2-, 4-, and 9-valent VLP HPV vaccines: What's ongoing, what's needed?

Preventive medicine·2021
Same author

IPVS statement on "Temporary HPV vaccine shortage: Implications globally to achieve equity".

Papillomavirus research (Amsterdam, Netherlands)·2020
Same author

Carcinogenic human papillomavirus infection.

Nature reviews. Disease primers·2016
Same author

Alternative dosage schedules with HPV virus-like particle vaccines.

Expert review of vaccines·2014

Area of Science:

  • Oncology
  • Virology
  • Immunology
  • Vaccinology

Background:

  • Cervical cancer is predominantly caused by specific genital human papillomaviruses (HPVs).
  • Preventing HPV infection through vaccination is a key anti-cancer strategy.
  • Traditional virus cultivation is challenging, necessitating alternative vaccine development approaches.

Purpose of the Study:

  • To evaluate the efficacy of human papillomavirus (HPV) L1 virus-like particle (VLP) vaccines.
  • To assess the safety and immunogenicity of HPV L1 VLP vaccines.
  • To explore future directions for HPV vaccine development.

Main Methods:

  • Generation of HPV L1 VLPs through synthesis and self-assembly of the major capsid protein.
  • Clinical trials (Phase III) to assess vaccine efficacy against persistent HPV infection and cervical intraepithelial neoplasia.

Related Experiment Videos

  • Evaluation of vaccine safety and immunogenicity.

    • Main Results:

    • HPV L1 VLP vaccines are immunogenic and demonstrate a good safety profile.
    • Evidence suggests protection against persistent HPV infection and cervical intraepithelial neoplasia.
    • Vaccine efficacy is likely HPV type-specific, requiring pre-exposure immunization.

    Conclusions:

    • HPV L1 VLP vaccines represent a promising strategy for cervical cancer prevention.
    • Further research is needed to determine the duration of protection and optimize vaccine strategies.
    • Second-generation vaccines may incorporate early antigens and alternative delivery systems for broader protection and accessibility.